FDA Approved: DOXAZOSIN — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approves Teva's supplemental application for doxazosin (doxazosin mesylate) under ANDA075536.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Hypertension

Drugs mentioned

• Doxazosin (doxazosin)

Snippet

SUPPL AP for DOXAZOSIN (DOXAZOSIN MESYLATE)